{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:40:52Z","timestamp":1767832852142,"version":"3.49.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T00:00:00Z","timestamp":1340755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0039741","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T22:06:59Z","timestamp":1340834819000},"page":"e39741","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":71,"title":["Development of AAVLP(HPV16\/31L2) Particles as Broadly Protective HPV Vaccine Candidate"],"prefix":"10.1371","volume":"7","author":[{"given":"Karen","family":"Nieto","sequence":"first","affiliation":[]},{"given":"Margit","family":"Weghofer","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Sehr","sequence":"additional","affiliation":[]},{"given":"Mirko","family":"Ritter","sequence":"additional","affiliation":[]},{"given":"Sebastian","family":"Sedlmeier","sequence":"additional","affiliation":[]},{"given":"Balasubramanyam","family":"Karanam","sequence":"additional","affiliation":[]},{"given":"Hanna","family":"Seitz","sequence":"additional","affiliation":[]},{"given":"Martin","family":"M\u00fcller","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Kellner","sequence":"additional","affiliation":[]},{"given":"Markus","family":"H\u00f6rer","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"Michaelis","sequence":"additional","affiliation":[]},{"given":"Richard B. S.","family":"Roden","sequence":"additional","affiliation":[]},{"given":"Lutz","family":"Gissmann","sequence":"additional","affiliation":[]},{"given":"J\u00fcrgen A.","family":"Kleinschmidt","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2012,6,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1002\/3527609318","article-title":"Infections causing human cancer.","author":"H Zur Hausen","year":"2006"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer.","volume":"348","author":"N Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.vaccine.2009.01.102","article-title":"Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20\u201338) peptide displayed on bacterial thioredoxin.","volume":"27","author":"I Rubio","year":"2009","journal-title":"Vaccine"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2010.10.017","article-title":"The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.","volume":"409","author":"I Rubio","year":"2011","journal-title":"Virology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virol.2006.08.037","article-title":"Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.","volume":"358","author":"K Kondo","year":"2007","journal-title":"Virology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/viro.1997.8649","article-title":"A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease.","volume":"234","author":"MS Campo","year":"1997","journal-title":"Virology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.","volume":"73","author":"K Kawana","year":"1999","journal-title":"J Virol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.","volume":"270","author":"RB Roden","year":"2000","journal-title":"Virology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.","volume":"83","author":"C Schellenbacher","year":"2009","journal-title":"J Virol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1073\/pnas.0800868105","article-title":"Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.","volume":"105","author":"HH Alphs","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.","volume":"101","author":"S Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1073\/pnas.162250899","article-title":"The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.","volume":"99","author":"Q Xie","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1073\/pnas.1001673107","article-title":"A viral assembly factor promotes AAV2 capsid formation in the nucleolus.","volume":"107","author":"F Sonntag","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1128\/JVI.05359-11","article-title":"The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes.","volume":"85","author":"F Sonntag","year":"2011","journal-title":"J Virol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.","volume":"21","author":"S Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/71021","article-title":"Genetic capsid modifications allow efficient re-targeting of adeno- associated virus type 2.","volume":"5","author":"A Girod","year":"1999","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1128\/JVI.74.18.8635-8647.2000","article-title":"Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.","volume":"74","author":"P Wu","year":"2000","journal-title":"J Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1089\/hum.2005.16.408","article-title":"Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism.","volume":"16","author":"N Muzyczka","year":"2005","journal-title":"Hum Gene Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0065-2660(09)67002-4","article-title":"Adeno-associated viral vectors and their redirection to cell-type specific receptors.","volume":"67","author":"S Michelfelder","year":"2009","journal-title":"Adv Genet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2174\/156652310793180706","article-title":"AAV\u2019s anatomy: roadmap for optimizing vectors for translational success.","volume":"10","author":"AM Mitchell","year":"2010","journal-title":"Curr Gene Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jgm.1392","article-title":"Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations.","volume":"11","author":"J Boucas","year":"2009","journal-title":"J Gene Med"},{"key":"ref22","article-title":"Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions.","author":"M Naumer","year":"2011"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2.","volume":"81","author":"R Gambhira","year":"2007","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.","volume":"199","author":"R Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents.","volume":"18","author":"R Calcedo","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/JVI.02190-08","article-title":"Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.","volume":"83","author":"KM Johnson","year":"2009","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1128\/JVI.00724-06","article-title":"Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells.","volume":"80","author":"TD Culp","year":"2006","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.00143-08","article-title":"Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.","volume":"82","author":"PM Day","year":"2008","journal-title":"J Virol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1128\/JVI.01631-08","article-title":"Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.","volume":"82","author":"PM Day","year":"2008","journal-title":"J Virol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1128\/JVI.01577-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.","volume":"81","author":"R Gambhira","year":"2007","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.virol.2005.04.011","article-title":"Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.","volume":"337","author":"DV Pastrana","year":"2005","journal-title":"Virology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.","volume":"270","author":"RB Roden","year":"2000","journal-title":"Virology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.vaccine.2006.11.049","article-title":"A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.","volume":"25","author":"K Slupetzky","year":"2007","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2007.11.003","article-title":"How do adjuvants work? Important considerations for new generation adjuvants.","volume":"27","author":"AS McKee","year":"2007","journal-title":"Immunity"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research.","volume":"5","author":"B Guy","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/JVI.80.6.2621-2630.2006","article-title":"Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.","volume":"80","author":"D Kuck","year":"2006","journal-title":"J Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-59745-457-5_14","article-title":"Virus-like particle and viral vector production using the baculovirus expression vector system\/insect cell system: adeno-associated virus-based products.","volume":"388","author":"MG Aucoin","year":"2007","journal-title":"Methods Mol Biol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fmicb.2011.00204","article-title":"Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.","volume":"2","author":"M Bartel","year":"2011","journal-title":"Front Microbiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1073\/pnas.90.18.8392","article-title":"Production of high-titer helper-free retroviruses by transient transfection.","volume":"90","author":"WS Pear","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.","volume":"321","author":"DV Pastrana","year":"2004","journal-title":"Virology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1110\/ps.8.11.2392","article-title":"Immunochemical evidence that cholesteryl ester transfer protein and bactericidal\/permeability-increasing protein share a similar tertiary structure.","volume":"8","author":"V Guyard-Dangremont","year":"1999","journal-title":"Protein Sci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.","volume":"13","author":"JN Roberts","year":"2007","journal-title":"Nat Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0039741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T01:02:52Z","timestamp":1594342972000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0039741"}},"subtitle":[],"editor":[{"given":"Lawrence","family":"Banks","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2012,6,27]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0039741","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,27]]}}}